Study of correlation between expression of bradykinin B2 receptor and pathological grade in human gliomas
Study of correlation between expression of bradykinin B2 receptor and pathological grade in human gliomas
复制标题
DOI：
10.1080/02688690500305555
复制
发表时间：
2005-01
影响因子：
1.1
通讯作者：
Yisong Zhao;Yixue Xue;Yunhui Liu;Wei Fu;Naijia Jiang;P. An;Ping Wang;Zhi-hang Yang;Yuqin Wang
中科院分区：
文献类型：
--
作者：
Yisong Zhao;Yixue Xue;Yunhui Liu;Wei Fu;Naijia Jiang;P. An;Ping Wang;Zhi-hang Yang;Yuqin Wang
在临床实践中，相同病理类型的脑肿瘤对缓激肽诱导的血肿瘤屏障(BTB)通透性的反应不同。肿瘤对缓激肽反应的差异性可能与缓激肽B2受体的表达水平有关。本研究采用新鲜人脑胶质瘤标本，检测不同病理分级脑胶质瘤中缓激肽B2受体的表达水平。肿瘤分级采用WHO分级标准。采用免疫组织化学和免疫印迹方法检测缓激肽B2受体在脑胶质瘤中的表达水平。在24例胶质瘤中，WHO I级8例，WHO II级8例，WHO III级8例。Western印迹和免疫组织化学均显示缓激肽B2受体定位于肿瘤细胞，而位于胶质瘤边缘的脑细胞几乎不表达B2受体。不同病理分级的脑胶质瘤中缓激肽B2受体的表达水平差异有统计学意义。B_2受体在三级脑胶质瘤中的表达顺序为：WHO I、WHO II、WHO III。检测人脑胶质瘤中缓激肽B_2受体的表达水平可能有助于筛选脑胶质瘤患者，以预测他们是否适合用缓激肽或其类似物打开血-瘤屏障。
In clinical practice there is a difference in response of the blood-tumour barrier (BTB) permeability induced by bradykinin in brain tumours with the same pathology. The variability in response of tumours to bradykinin is likely to be related to the expression level of bradykinin B2 receptor. This study used fresh human glioma samples to determine the expression level of bradykinin B2 receptor on gliomas with different pathological grades. The grade of tumour was classified using the WHO classification. To determine the bradykinin B2 receptor expression level in gliomas, Immunohistochemistry and Western blot methods were used. In 24 cases of gliomas there were eight cases of WHO I glioma, eight cases of WHO II glioma and eight cases of WHO III glioma. Both Western blot and immunohistochemistry showed bradykinin B2 receptors localized on tumour cells, whilst brain cells at the edge of the glioma hardly expressed B2 receptor. There were significant differences of bradykinin B2 receptor expression level among different pathological grades of glioma. The expression of B2 receptor in the three grades of glioma was in the order of WHO I < WHO II < WHO III. Determination of bradykinin B2 receptor expression level in human glioma may be useful in screening glioma patients to predict whether they will be suitable for opening of the blood – tumour barrier with bradykinin or its analogue.